Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514213 · ClinicalTrials.gov registry record · Phase 1
Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
NCT02514213 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT02514213, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
Interventions
- BIOLOGICAL 2mg INO-5150 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 8.5mg INO-5150 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- BIOLOGICAL 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P
- DEVICE Electroporation using CELLECTRA®-5P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514213
The ClinicalTrials.gov registry entry for NCT02514213 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 2mg INO-5150 and electroporation device CELLECTRA®-5P is the first listed.
NCT02514213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02514213 about?
NCT02514213 is a clinical study titled "Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer". This is a phase I, open-label trial to evaluate the safety and immunogenicity of INO 5150 alone or in combination with INO-9012 when delivered intramuscularly (IM) followed by electroporation (EP) in men with biochemically relapsed prostate cancer.
What is the current status of trial NCT02514213?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2015-07. Estimated completion is 2017-12-12.
What interventions are being tested in trial NCT02514213?
The interventions under investigation include: 2mg INO-5150 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 8.5mg INO-5150 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P (BIOLOGICAL), 8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P (BIOLOGICAL), Electroporation using CELLECTRA®-5P (DEVICE).
Who is sponsoring clinical trial NCT02514213?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.